| TGA Action ID |
RC-2025-RN-00827-1 |
| Type of Product |
Medical Device |
| Product Name/Description |
Catalyft PL & PL40 Expandable Interbody System
Multiple material descriptions, material numbers and CFN's |
| ARTG Number |
126313 |
| Action Type |
Product Correction |
| Action Level |
Hospital |
| Hazard Classification |
Class II |
| Reason for the Action |
Medtronic’s Catalyft PL & PL40 expandable interbody system has been reported to have loss of lordosis, which may also be described as loss of height or collapse. While loss of implant lordosis and/or subsidence is a known risk associated with expandable interbody implants, Medtronic’s investigation has identified labelling updates that can further mitigate this risk for loss of lordosis to occur.
Use of this device without following the Instructions for Use or surgical technique guide could result in potential adverse events such as loss of lordosis, migration, subsidence and/or neurological injury. Some patients have required revision surgery due to pain or pseudoarthrosis associated with loss of lordosis. The majority of complaints reporting loss of lordosis were asymptomatic findings detected on routine post operative imaging. |
| Instructions for Customers/Users |
Customers are to - Review the updated Surgical Technique Guide and Instruction for Use (IFU). |
| Action Commencement Date |
2/10/2025 |
| Responsible Entity |
|
| Contact Information |
0418 868 733 - Tingyu Yang, Medtronic Australasia |